KRAS and neoplasm: It was found in the cytoplasm and at the cell membrane and correlated with diverse clinicopathological patient characteristics, including tumor type according to the Lauren, mucin phenotype, microsatellite status, E-cadherin and β-catenin expression, KRAS genotype and PD-L1 status in tumor cells.